Grace had calculated her BMI three times before her appointment. Forty-seven years old, a finance director, someone who trusted spreadsheets and data — and yet she sat in the waiting room of our Malta clinic with her phone calculator open, convinced…
Last reviewed by the Carisma Medical Team — 2026
Grace had calculated her BMI three times before her appointment. Forty-seven years old, a finance director, someone who trusted spreadsheets and data — and yet she sat in the waiting room of our Malta clinic with her phone calculator open, convinced she had the number wrong. She was certain she was just under the threshold. Certain she would be turned away.
What Grace did not know was that her PCOS diagnosis — the one her GP had noted years ago and then largely set aside — meant her Mounjaro eligibility Malta BMI calculation was not the whole story. The consultation itself is where those nuances get properly assessed. By the end of that first appointment, she had a clear picture of where she stood clinically, what her options were, and why her previous attempts at weight management had never quite worked the way she hoped.
Understanding Mounjaro eligibility is not as simple as typing your height and weight into a calculator.
Key Takeaways - Mounjaro eligibility Malta BMI threshold starts at 30, but BMI 27+ qualifies with a weight-related health condition - Conditions like PCOS, type 2 diabetes, and hypertension can lower the qualifying BMI threshold - A full clinical assessment looks beyond your BMI number — blood work and medical history matter - Absolute contraindications include medullary thyroid cancer history, pregnancy, and pancreatitis - Results may vary for each individual; a proper eligibility consultation gives you a clear, personalised answer
This article walks you through the clinical criteria — what the evidence actually says, what conditions can affect eligibility, what your doctor will look for beyond a number, and what your options are if Mounjaro is not the right fit for you right now.
What Is Mounjaro and Why Is It Prescription-Only?
Mounjaro (tirzepatide) is a once-weekly injectable medication approved by the European Medicines Agency (EMA) in November 2023 for chronic weight management in adults with obesity or overweight. It belongs to a class of medications known as dual GIP and GLP-1 receptor agonists — meaning it works on two separate glucagon-like peptide pathways simultaneously to support appetite suppression and metabolic rate regulation.
Unlike single-action GLP-1 medications, tirzepatide activates two separate incretin receptor pathways simultaneously. GLP-1 receptors in the hypothalamus suppress appetite and slow gastric emptying, extending the feeling of fullness after meals. GIP receptors — found in adipose tissue and the central nervous system as well as the pancreas — appear to contribute independently to adipose metabolism and energy expenditure. This dual mechanism is proposed to explain tirzepatide's superior weight loss outcomes compared to GLP-1-only agents in head-to-head studies. The clinically supervised nature of these programmes is what makes them both safe and effective.
In the SURMOUNT-1 clinical trial, involving 2,539 adults without type 2 diabetes followed over 72 weeks, participants using tirzepatide at the 15mg dose achieved a mean body weight reduction of 20.9%, compared to 3.1% in the placebo group. At that dose, 56.7% of participants achieved 20% or more body weight reduction — a threshold previously unachievable with any approved anti-obesity medicine (Jastreboff AM et al., NEJM 2022).
Mounjaro is prescription-only because it requires clinical assessment, medical supervision, and ongoing monitoring. It is not appropriate for everyone, and the criteria for eligibility are grounded in both efficacy and safety evidence. In a medically supervised programme, those criteria protect you — not restrict you arbitrarily.
The BMI Thresholds for Mounjaro in Malta
BMI 30 or above: standard eligibility
The EMA-approved indication for tirzepatide includes adults with a BMI of 30 kg/m² or above, which is classified as obesity. This is the standard threshold — if your BMI sits at 30 or higher, you meet the core weight criterion for Mounjaro and the next step is a clinical assessment to evaluate the full picture.
BMI 27–29.9: eligible with a weight-related health condition
This is the category that Grace fell into, and the one most people do not realise exists. Per the EMA approved indication, adults with a BMI of 27 kg/m² or above — classified as overweight rather than obese — are also eligible for Mounjaro if they have at least one weight-related comorbidity. The qualifying conditions include type 2 diabetes, hypertension (high blood pressure), dyslipidaemia (high cholesterol or abnormal lipid levels), obstructive sleep apnoea, or cardiovascular disease.
This means that BMI in the range of 27–29.9 with a relevant health condition can qualify you. Many women in Malta who dismiss themselves as "not heavy enough" for medical weight loss are, in fact, clinically eligible.
Why your weight-to-height ratio is just one part of the picture
BMI is a population-level screening tool, not a precise measure of individual health risk. It does not distinguish between fat mass and lean mass, does not account for fat distribution (visceral versus subcutaneous), and does not capture metabolic health or insulin resistance. At Carisma Slimming, our team in Malta uses BMI as a starting reference point — not a verdict. Your full eligibility assessment involves a much broader clinical picture, which we cover later in this article. Results may vary for each individual based on starting point, health history, and individual response to treatment.
Health Conditions That Can Qualify You at a Lower BMI
If your BMI falls between 27 and 29.9, the clinical question becomes: do you have a weight-related health condition? Here are the most common qualifying conditions our team in Malta assesses.
Type 2 diabetes or pre-diabetes
Type 2 diabetes is among the clearest qualifying conditions for Mounjaro at a lower BMI threshold. Tirzepatide was originally developed as a diabetes medication and has a robust evidence base in this population — the SURMOUNT-2 trial demonstrated 12.8% (10mg) and 14.7% (15mg) body weight reduction in adults with type 2 diabetes over 72 weeks (Garvey WT et al., Lancet 2023).
Pre-diabetes — where blood glucose levels are elevated but not yet at the diagnostic threshold for type 2 diabetes — is also a clinically significant condition that your doctor may consider. Weight loss of even 5–10% has been shown to meaningfully reduce the risk of progression to type 2 diabetes. Appetite suppression from tirzepatide can make reaching that threshold far more sustainable than conventional dietary approaches alone.
Hypertension, high cholesterol, sleep apnoea
High blood pressure, dyslipidaemia (elevated LDL cholesterol, low HDL cholesterol, or elevated triglycerides), and obstructive sleep apnoea are all recognised weight-related comorbidities under the EMA indication. Many women in their forties and fifties carry one or more of these diagnoses — sometimes without fully connecting them to their weight. If your blood pressure is managed on medication, or you are on a statin, or you have been told you snore heavily or stop breathing in your sleep, these are relevant details to bring to your eligibility consultation.
Polycystic ovarian syndrome (PCOS)
PCOS is a hormonal condition that affects insulin regulation, weight distribution, and metabolic health. It is one of the most common endocrine disorders in women of reproductive age and is frequently associated with weight gain that proves resistant to conventional diet and exercise interventions — not because of a lack of effort, but because the underlying hormonal environment actively works against it.
PCOS is not listed as a standalone qualifying comorbidity in the EMA label, but it frequently co-exists with insulin resistance, pre-diabetes, or dyslipidaemia — conditions that do qualify. Our clinical team in Malta will assess your full hormonal and metabolic picture at consultation. Women with PCOS are not automatically excluded, and in many cases the combination of relevant metabolic markers means eligibility is established through those overlapping conditions.
If you have PCOS and have been wondering about your options, schedule your free consultation with our team in Malta to get a complete clinical picture rather than ruling yourself out on assumption.
Who Is Not Eligible for Mounjaro
Eligibility for Mounjaro is not only about whether you meet the weight or BMI criteria. There are specific contraindications — medical reasons that make the treatment unsafe — and your healthcare provider will screen for these carefully during assessment.
Absolute contraindications: thyroid cancer history, pancreatitis
Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). These are rare conditions, but they are important to disclose. If you have ever been told you or a close family member has had medullary thyroid cancer or MEN2, this would typically preclude Mounjaro from consideration.
A personal history of acute pancreatitis is also a contraindication. While causality between GLP-1 class medications and pancreatitis has not been definitively established in clinical trials, the precautionary guidance from prescribers and regulators is to avoid these medications in individuals with a relevant pancreatitis history.
Pregnancy, breastfeeding, and planning to conceive
Mounjaro is not appropriate during pregnancy or breastfeeding, and women who are actively trying to conceive are generally advised against starting it. If you are using contraception and start Mounjaro, your doctor will discuss timing and the recommendation to use contraception consistently during treatment. Women who become pregnant during treatment should discontinue and inform their healthcare provider immediately.
Other medications that interact
Mounjaro slows gastric emptying, which can affect the absorption of oral medications — including oral contraceptives. Your doctor will review your current medication list carefully at assessment. Known hypersensitivity to tirzepatide or any of its excipients is also an absolute contraindication.
What Your Doctor Checks Beyond BMI
The eligibility consultation is not a weigh-in. It is a clinical assessment designed to build an accurate picture of your health, your history, and whether Mounjaro is the right tool for where you are right now.
Blood work and vitals
A baseline blood panel typically includes fasting glucose and HbA1c (to assess blood sugar regulation and screen for diabetes or pre-diabetes), lipid panel (total cholesterol, LDL, HDL, triglycerides), thyroid function (TSH and free T4), liver function tests, kidney function markers (eGFR, creatinine), and full blood count. Blood pressure, resting heart rate, and weight are recorded. In some cases, a body composition scan may be included to assess fat mass versus lean mass — a more clinically meaningful baseline than BMI alone.
These results are not just a formality. They establish your clinical starting point, identify any conditions that affect prescribing decisions, and provide the baseline against which your progress will be tracked throughout a medically supervised programme. Some women walk in having never been told their blood sugar or cholesterol sits in a borderline range — the assessment itself can be genuinely informative for your wider health picture.
Weight history and previous interventions
Your doctor will also take a weight history: when your weight began to change, what interventions you have tried, what results those produced, and what your experience has been with diet programmes, medications, or clinical support in the past. This context matters. It informs both your eligibility and the design of a programme that is realistic and sustainable for you specifically.
Results may vary for each individual, and a thorough history helps our clinical team in Malta understand not just whether Mounjaro is appropriate, but how to support you through it effectively. Our GLP-1 weight loss programme is designed with exactly this kind of personalised clinical foundation.
What If You Do Not Meet the Criteria Today?
Not everyone who comes to an eligibility consultation at Carisma Slimming leaves with a prescription for Mounjaro. That does not mean there is no path forward.
Other medical and non-surgical slimming options in Malta
Our team in Malta offers a range of medically supervised programmes and treatments for women at different starting points. Our GLP-1 medical weight loss programme covers multiple medication options beyond Mounjaro, including alternatives that may have different eligibility criteria. Non-injectable approaches — supported nutritional programmes, body composition tracking, and clinical accountability structures — are also available and meaningful for women who are not yet ready for or eligible for injectable medication.
Non-surgical treatments such as fat freezing (cryolipolysis), EMS muscle stimulation, and lipocavitation can be valuable adjuncts or standalone approaches depending on your goals and clinical picture. These are discussed with you during your consultation based on what is relevant for where you are now. You can also browse our full range of slimming packages to understand what non-injectable options might complement your programme.
How to prepare for a future assessment
If you do not meet the BMI criteria today, or if a current health condition needs to be addressed before Mounjaro can be safely prescribed, your doctor will tell you what that pathway looks like. In some cases, weight loss through an initial supported programme can shift your BMI or health profile in ways that open up additional options over time.
Book a free consultation with our team in Malta — the assessment is never a dead end. It is the beginning of a structured conversation about what is clinically appropriate and what is possible for you.
Frequently Asked Questions About Mounjaro Eligibility in Malta
What is the minimum BMI for Mounjaro in Malta?
The EMA-approved indication sets the standard threshold at a BMI of 30 kg/m² or above (obesity). However, adults with a BMI of 27 kg/m² or above (overweight) are also eligible if they have at least one weight-related comorbidity — such as type 2 diabetes, hypertension, high cholesterol, obstructive sleep apnoea, or cardiovascular disease. BMI alone does not determine eligibility. A full clinical assessment by a qualified prescriber is required to establish whether Mounjaro is appropriate for you as an individual.
Can I get Mounjaro in Malta if I have a BMI of 27?
Yes, it is possible. A BMI of 27 qualifies under the EMA indication if you have at least one weight-related health condition. Common qualifying conditions include type 2 diabetes or pre-diabetes, hypertension managed on medication, dyslipidaemia (high cholesterol), or obstructive sleep apnoea. An eligibility consultation with our clinical team in Malta will assess your full health picture to determine whether you meet the criteria. Many women who believe they are not eligible at a BMI of 27 find that an existing diagnosis changes the picture entirely.
Does PCOS make me eligible for Mounjaro at a lower BMI?
PCOS itself is not listed as a standalone qualifying comorbidity in the EMA-approved indication. However, PCOS frequently co-exists with insulin resistance, pre-diabetes, dyslipidaemia, or other metabolic conditions that do qualify — and these overlapping conditions are assessed during your eligibility consultation. If you have PCOS and a BMI between 27 and 29.9, it is worth attending a clinical assessment rather than ruling yourself out. Our team in Malta is experienced in assessing women with complex hormonal histories, and the nuances of your individual case are best evaluated in person.
Are there any health conditions that make Mounjaro unsafe?
Yes. Mounjaro is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). It is also contraindicated in current pregnancy, breastfeeding, and in individuals with known hypersensitivity to tirzepatide. A history of acute pancreatitis is also a contraindication. Your doctor will screen for these during your assessment and will review your full medication list to identify any interactions or prescribing considerations. Your safety at every stage of a medically supervised programme is the first priority.
What blood tests are done before starting Mounjaro?
A standard pre-treatment blood panel typically includes fasting glucose and HbA1c, a full lipid panel, thyroid function (TSH and free T4), liver function tests, kidney function markers, and a full blood count. Blood pressure and resting heart rate are also recorded. These tests establish your clinical baseline, screen for relevant contraindications, and identify any conditions — such as undiagnosed pre-diabetes or hypothyroidism — that should be addressed as part of your programme. Results are reviewed with you at your appointment, and they inform both the prescribing decision and the overall support plan.
Can I get Mounjaro in Malta without a diagnosed health condition?
If your BMI is 30 or above, you do not need a diagnosed comorbidity to be considered eligible under the EMA approved indication. If your BMI is between 27 and 29.9, at least one qualifying weight-related health condition is required. In practice, many women who come for assessment in Malta and believe they have no diagnosed conditions discover relevant markers in their pre-treatment blood work — elevated blood sugar, high cholesterol, or blood pressure readings that place them in a qualifying category. The consultation itself is where that picture becomes clear, which is why attending an assessment is always the right first step rather than self-excluding based on an assumption.
Book an Eligibility Consultation at Carisma Slimming Malta
You deserve a clear answer — not a calculator and a guess. If you have been wondering whether Mounjaro is an option for you, the right place to start is a proper clinical assessment with a qualified team, not more time spent second-guessing your BMI at midnight.
At Carisma Slimming in Malta, our medically supervised eligibility consultations are designed to give you exactly that: a complete picture of where you stand clinically, what your options are, and what a programme designed around your health history would look like. No judgement. No assumptions. Just facts, support, and a clear next step.
Book your free eligibility consultation at Carisma Slimming today — and find out where you actually stand.
Picture yourself eight weeks from now, not still wondering, but already on a programme built for you. Walking up two flights of stairs and not giving it a second thought. Sleeping better. Feeling like your body is finally working with you rather than against you.
That clarity starts with one appointment.
With you every step, Katya
Image Credits
Hero Image URL: https://images.pexels.com/photos/7579823/pexels-photo-7579823.jpeg?auto=compress&cs=tinysrgb&dpr=2&h=650&w=940 • Photographer: cottonbro studio • Pexels Page: https://www.pexels.com/photo/woman-in-white-suit-with-stethoscope-talking-to-a-person-7579823/ • Alt text: Mounjaro eligibility Malta BMI assessment — female doctor in white coat consulting a patient in a warm clinical setting • Caption: Mounjaro eligibility is assessed through a one-to-one clinical consultation with your doctor. • Filename: blog-06-hero-doctor-consultation.jpg • Query used: doctor patient consultation woman
Inline Image URL: https://images.pexels.com/photos/15319047/pexels-photo-15319047.jpeg?auto=compress&cs=tinysrgb&dpr=2&h=650&w=940 • Photographer: beyzahzah • Alt text: Female nutritionist in a bright office holding broccoli surrounded by fresh fruits, representing healthy lifestyle criteria • Query used: medical wellness consultation woman smiling
More from the blog
